Antibiotic Resistance Pattern of Shigella spp. Among Gastroenteritis Patients at Tertiary Care Hospital in Pokhara, Nepal
Shigellosis, a disease caused by Shigella species. It is a major public health problem in developing nations like Nepal, where communities having poverty; poor sanitation, personal hygiene, and water supplies. The main aim of our study is to isolate and identify Shigella spp. from gastroenteritis patients and to find out its drug resistance pattern.
A cross-sectional study was carried out based on routinely attending outpatients and inpatients. A total of 225 stool samples collected from gastroenteritis patients were processed from 20 April to 24 September 2014 in Western Regional Hospital, Pokhara, Nepal. Standard microbiological procedures were followed for the isolation of Shigella spp. After that slide agglutination kit method was used for identification of Shigella spp. Finally, Kirby-Bauer disc diffusion method was done for an antimicrobial resistance test.
Of the total 225 gastroenteritis patients, 133 were detected as bacterial positive cases. Among positive cases, Shigella spp. was identified in 10.5%. Age wise, an infection rate of Shigella in patients <15-years old was found higher i.e. 7.3% than in patients ≥ 15 years old i.e. 4.5% with the (p = 0.432) at 95% CI. The infection rate of S. dysenteriae, S. flexneri, and S. sonnei was detected in 28.6%, 57.1%, and 14.3% respectively. For the antimicrobial test, eight types of antibiotics were used. The most resistance pattern of isolated Shigella spp. was found in nalidixic acid, and co-trimoxazole 92.8% followed by ampicillin 64.3% and ciprofloxacin 42.8% etc.
Our study reported that endemicity of Shigellosis with S. flexneri is the predominant group in gastroenteritis patients. This finding suggests that co-trimoxazole, nalidixic acid, ciprofloxacin and ampicillin should not be used experimentally as first-line drugs for shigellosis treatment.
Copyright (c) 2017 Nepal Journal of Biotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The manuscript submitted to NJB must be an original contribution, not previously published and is not under consideration for publication elsewhere. When the manuscript is accepted for publication, the authors agree to automatically transfer of the copyright of the article to the publisher. It should grant permission to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the Nepal Journal of Biotechnology copyright and license agreement
Authors transfer copyright to the publisher as part of a journal publishing agreement, but have the right to: Share their article for Personal Use, Internal Institutional Use and Scholarly Sharing purposes, with the Creative Commons CC-BY-NC-ND license for author manuscript versions under which you must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use Retain patent, trademark and other intellectual property rights (including raw research data). Author must provide proper attribution and credit for the published work. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.